On the evening of February 9, Yuandong Bio issued an announcement stating that its wholly-owned subsidiary, Chengdu Youluo Biotechnology Co., Ltd., is conducting a Phase I clinical trial of its independently developed Class 1 biological drug EP-0210 monoclonal antibody injection for the treatment of inflammatory bowel disease, and recently completed the dosing of the first subject.
The announcement shows that EP-0210 monoclonal antibody injection is a humanized IgG1 monoclonal antibody drug that targets human tumor necrosis factor-like ligand 1A (TL1A). Its proposed indication is inflammatory bowel disease. Its mechanism of action is to bind to human TL1A efficiently and block the TL1A-mediated pro-inflammatory signaling pathway, thereby playing a role in the treatment of inflammatory bowel disease.
Yuandong Bio stated that TL1A antibody drug development is one of the most promising emerging targets in the field of inflammatory bowel disease research, and currently there are no drugs targeting the same target on the market globally. The companies with the most advanced development progress globally are Merck, Sanofi, and Roche/Pfizer, whose TL1A antibody drugs are all in Phase III clinical trials. In China , 3SBio , Zhixiang Jintai , and Huashen Zhiyao have drugs targeting the same target that have entered Phase I clinical trials .

https://finance.sina.com.cn/jjxw/2026-02-09/doc-inhmfqci6253899.shtml